Response to Representative Schakowsky’s Questions for the Record for House Energy & Commerce Committee (Subcommittee on Consumer Protection and Commerce) Hearing on 'Profits Over Consumers: Exposing How Pharmaceutical Companies Game the System'
Response to Representative Schakowsky’s Questions for the Record, 2019
2 Pages Posted: 13 Jan 2020
Date Written: October 22, 2019
After my testimony at the House Energy & Commerce Committee hearing, I addressed Rep. Schakowsky's questions relating to a potential FTC report on product hopping.
I explained that such a report would be helpful in obtaining information on the frequency and types of "product hopping" (by which drug companies switch from one version of a drug to another to delay generic entry). A report also would shed light on the potential anticompetitive harms of "soft switches" (in which the old drug is left on the market).
Finally, I discussed the types of information that could appear in the report, including the extent of product hopping and the effects on profitability and consumers.
Keywords: product hopping, drugs, pharmaceuticals, FTC
JEL Classification: I18, K21, L40, L41, L43, L65, O34, O38
Suggested Citation: Suggested Citation